Analysis of Low Dose Aspirin on Platelet Aggregation Percentage in High-Risk Pregnancy Hypertension

Abstract

Objective: Low dose aspirin (LDA) is one of platelet aggregation agents in high-risk pregnancy that is believed to prevent complication by inhibiting thromboxane A2 as a strong vasoconstrictor in platelet. It can inhibit platelet aggregation involved in pathophysiology of pregnancy hypertension. The aim of this study is to analyse the effect of LDA on platelet aggregation in pregnant patient with high-risk hypertension. \nMaterial and methods: A prospective observational method was conducted in this study. It was approved by the Ethics Committee of Haji Teaching Hospital Surabaya. Data was collected from July to September 2018 involving 18 patients divided into three groups who have age of 35-39 years old in the majority. The range of gestational age in this study was 19-37 weeks. Platelet aggregations on plasma were measured before and 14 – 30 days after LDA use. The collected data were statistically analyzed by using a paired t-test. \nResults: Platelet aggregation percentage using collagen agonists was an increase of 0.8% (p > 0.05) in the old patient group and followed by 6% (p > 0.05) in the group of patients who did not get LDA. Whereas in the group of new patients showed a decrease of 6% (p > 0.05). While ADP agonists showed that the group of new patients decreased by 17% (p > 0.05), followed by the group of patients who did not use LDA of 9% (p > 0.05) and the old patient group was 4% (p > 0.05). \nConclusions: Low-dose aspirin use did not affect a decrease in platelet aggregation values.